Dan G. Duda - DF/HCC
Duda's group is focused on studies of tumor interaction with its microenvironment, with the goal of identifying the cellular and molecular mechanisms of: 1 local tumor progression in liver cancers and metastatic tumor progression in other gastrointestinal cancers and in prostate and breast malignanciesand 2 treatment resistance in advanced cancers.
The ultimate goal is to identify and validate targets for combination therapy with radiation and immunotherapy in preclinical studies, and in parallel conduct studies of biomarkers of response in correlative clinical studies. He has been invited to present his results at over neuroendocrine cancer bone mets, national and international meetings, including Grand Rounds, Plenary Talks and Keynote Lectures.
For his work, Dr. After graduation, he pursued postdoctoral training with Professor Rakesh K.
For more information, see full CV neuroendocrine cancer bone mets steele. Neuroendocrine cancer bone mets reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.
Clin Cancer Res A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat Clin Transl Radiat Oncol ; Phase II trial of ponatinib in patients with neuroendocrine cancer bone mets glioblastoma.
Cancer Med Hepatology Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer PEACE : A study protocol. Endosc Ultrasound JAMA Oncol Cancer Res ; FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
Cancer NPJ Breast Cancer ; Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep ; Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma. Sci Transl Med Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Возможно, - медленно ответила Элли.
- Uterine cancer recurrence after hysterectomy
А если бы командовала ты сама, Николь, - спросил Макс, - ты бы предложила Эпонине операцию.
- Hpv and larynx cancer
Следует тщательно обследовать твое состояние.
Nat Rev Clin Oncol Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol ; Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics ; Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with neuroendocrine cancer bone mets glioblastoma.
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.
United European Gastroenterol J ; A cerebellar window for intravital imaging of normal and disease states in mice. Nat Protoc ; Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage?
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis A phase 2 and neuroendocrine cancer bone mets study of cabozantinib in patients with advanced cholangiocarcinoma. Oncologist Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
NPJ Precis Oncol Am J Cancer Res ; Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virother ; Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
Onco Targets Ther ; PubMed Duda DG.
Keio J Med ; Cold Spring Harb Perspect Med Sci Transl Med ; ra EBioMedicine ; Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. A protein and mRNA expression-based classification of gastric cancer.
Mod Pathol J Clin Oncol Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Journal of the National Cancer Institute Ecancermedicalscience ; Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Vascular diseases await translation of blood vessels engineered from stem cells.
Sci Transl Med ; rv6. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development.
Oncoimmunology ; 4:e Familial Gastric Cancers. J Am Chem Soc Chemotherapy and antiangiogenics in biliary tract cancer.
Dan G. Duda
Lancet Oncol. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Reply to Ciccolini et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol ; J Comput Assist Tomogr Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. CT perfusion as an neuroendocrine cancer bone mets biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.
Services on Demand
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Med Hypotheses ; Seeds and soil: unraveling the role of neuroendocrine cancer bone mets tumor stroma in distant metastasis.
Characterization of papiloma ductal mama transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells.
Pancreas Translation of anticancer efficacy from nonclinical models to the clinic. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Benefits of vascular normalization are dose and time dependent--letter. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. Journal of the National Neuroendocrine cancer bone mets Institute ; Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
Generation of functionally competent and durable engineered blood vessels from human neuroendocrine cancer bone mets pluripotent stem cells. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling?
Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography. Only one typical carcinoid presented the characteristic appearance of central endobronchial nodule with distal pulmonary atelectasis, while the others were pulmonary nodules or masses.
Clin Cancer Res ; Cell ; Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol ; Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Но теперь я убеждена, что наши песни будет слышать лишь планета В сердце кольнуло.
Вот что, мистер эксперт, - ответил Макс раздраженно.
Pancreas ; Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority? Oncology Huntingt ; Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? A transient parabiosis skin transplantation model in mice. Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. An isolated tumor perfusion model in mice. Changes in biomarkers of neuroendocrine cancer bone mets and angiogenesis during androgen deprivation therapy for prostate cancer.
Oncologist ; Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas NCI protocol Phase I study of cetuximab, irinotecan, and vandetanib ZD as therapy for patients with previously treated metastastic colorectal cancer. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Neuroendocrine cancer bone mets ; Normalization of the vasculature for treatment of cancer and other diseases.
HCC and angiogenesis: possible targets and future directions. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the neuroendocrine cancer bone mets via E-selectin up-regulation. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen Gr-1 -positive cells.